Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 609

A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 583

A Serological Biomarker of Active MMP3, but Total MMP3, Can Early Assess Treatment Efficacy and Differentiate Doses of Tocilizumab and an Early Change in Active MMP3, but Not Total MMP3, Is Associated with Radiographic Change at 1 Year

9:00AM-11:00AM: Abstract Number: 547

Abatacept Does Not Improve Subclinical Atherosclerosis Despite Good Response in Rheumatoid Arthritis: A Cohort Study

9:00AM-11:00AM: Abstract Number: 563

Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 589

Adalimumab Concentration at 16 Weeks of Treatment Is Associated with Treatment Discontinuation within One Year

9:00AM-11:00AM: Abstract Number: 599

An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry

9:00AM-11:00AM: Abstract Number: 573

Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 551

Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study

9:00AM-11:00AM: Abstract Number: 617

Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients

9:00AM-11:00AM: Abstract Number: 582

Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital

9:00AM-11:00AM: Abstract Number: 553

Body Mass Index Does Not Influence the Efficacy of Abatacept in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study

9:00AM-11:00AM: Abstract Number: 549

Calprotectin (MRP8/MRP14), a Major Leukocyte Protein, Is Highly Associated to Ultrasound Detected Synovitis and Is Responsive to Biologic Treatment

9:00AM-11:00AM: Abstract Number: 604

Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity

9:00AM-11:00AM: Abstract Number: 550

Can Anti-TNF-Induced Autoantibody Conversion be Reversed By Switching to Abatacept Therapy in Patients with RA on Background MTX?

9:00AM-11:00AM: Abstract Number: 548

Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab

9:00AM-11:00AM: Abstract Number: 613

Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis

9:00AM-11:00AM: Abstract Number: 587

Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio

9:00AM-11:00AM: Abstract Number: 595

Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab

9:00AM-11:00AM: Abstract Number: 570

Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody: An Integrated Pharmacokinetic and Pharmacodynamic Approach for Phase II Studies in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 557

Early Intensification of Treatment Induces Superior Outcomes in Two Randomized Trials According to Predicted Vs. Observed Radiographic Progression in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 598

Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit

9:00AM-11:00AM: Abstract Number: 602

Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study

9:00AM-11:00AM: Abstract Number: 620

Evaluation of Patients from the Non-Biologic Arms of Inflammatory Arthritis Clinical Trials Identifies Several Predictors of Remission, As Well As, Distinct Responder Subgroups

9:00AM-11:00AM: Abstract Number: 562

Evaluation of T Helper Cell 1(Th1) – and T Helper Cell 17(Th17) – Associated Chemokines As Prognostic Biomarkers for Tumor Necrosis Factor (TNF) Inhibitor Therapy in Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 590

Expression Levels of Selected Genes May Predict Response to TNF Alpha Blockers or Rituximab in the Individual Rheumatoid Arthritis Patient

9:00AM-11:00AM: Abstract Number: 565

Factors Associated with Sustained Response in Patients with Rheumatoid Arthritis Who Received Rituximab within the US Corrona Registry

9:00AM-11:00AM: Abstract Number: 566

Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib

9:00AM-11:00AM: Abstract Number: 559

Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy

9:00AM-11:00AM: Abstract Number: 560

Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept

9:00AM-11:00AM: Abstract Number: 606

Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 561

Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 556

Induction-Maintenance in Early RA: A Meta-Analysis of Trials Using MTX Plus Adalimumab As Induction Therapy

9:00AM-11:00AM: Abstract Number: 597

JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 619

Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II

9:00AM-11:00AM: Abstract Number: 596

Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 571

Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 574

Metabolomic Profiling Predicts Outcome of Rituximab Therapy in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 579

Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 605

Monitoring of Epstein Barr Virus, Cytomegalovirus and Varicella Zooster Virus Load in Patients Receiving Tocilizumab for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 569

Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy

9:00AM-11:00AM: Abstract Number: 554

On Drug and Drug-Free Remission By Baseline Disease Duration: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 581

Optimization of Treatment Intervals of Tocilizumab and Golimumab By Measuring Serum Trough Levels in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 585

Outcomes after Discontinuing Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis: 2 Years of ‘post-Golimumab’ after Completion of the 5-Year Extension Study in Korea

9:00AM-11:00AM: Abstract Number: 555

Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 584

Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry

9:00AM-11:00AM: Abstract Number: 576

Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 593

Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy

9:00AM-11:00AM: Abstract Number: 575

Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients

9:00AM-11:00AM: Abstract Number: 572

Predictors of Long-Term Retention of Infliximab and Golimumab in Rheumatoid Arthritis: An Analysis from a Prospective, Observational Registry

9:00AM-11:00AM: Abstract Number: 588

Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance

9:00AM-11:00AM: Abstract Number: 616

Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD

9:00AM-11:00AM: Abstract Number: 610

Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy

9:00AM-11:00AM: Abstract Number: 567

Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature

9:00AM-11:00AM: Abstract Number: 615

Rituximab Non Responders Fail to Down Regulated CD19 on Naive B Cells

9:00AM-11:00AM: Abstract Number: 591

Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis

9:00AM-11:00AM: Abstract Number: 608

Safety of Surgery in Patients with Rheumatoid Arthritis Treated By Abatacept: Data from the French Orencia in Rheumatoid Arthritis (ORA) Registry

9:00AM-11:00AM: Abstract Number: 607

Serum Progranulin (PRGN) Level Is Not a Biomarker for Responsiveness to Tumor Necrosis Factor (TNF)-Antagonist Therapy in Rheumatoid Arthritis (RA) Patients

9:00AM-11:00AM: Abstract Number: 601

Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis

9:00AM-11:00AM: Abstract Number: 578

Study of the Production of Antinuclear Antibodies and Anti-Ds DNA Antibodies in Rheumatoid Arthritis Patients Treated with TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 568

Superiority of Initial Combination- over Step up Therapy in Treatment to the Target of Remission in Daily Clinical Practice in Early Rheumatoid Arthritis Patients: Results from the DREAM Registry

9:00AM-11:00AM: Abstract Number: 618

The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA

9:00AM-11:00AM: Abstract Number: 611

The Rapid Kinetics of Optimal Treatment with Subcutaneous Methotrexate in Early Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 552

The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab

9:00AM-11:00AM: Abstract Number: 612

Thromboembolic Events Are Not Associated with Anti-Adalimumab Antibodies

9:00AM-11:00AM: Abstract Number: 614

Time to First Signs of Loss of Response in Rheumatoid Arthritis Patients Treated with Anti TNF Agents: Correlations with Serum Drug Level, Immunogenicity and Csdmard Association

9:00AM-11:00AM: Abstract Number: 586

Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 600

Tocilizumab Serum Trough Levels and Disease Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 580

Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice

9:00AM-11:00AM: Abstract Number: 558

Tuberculosis Risk Among Patients with Rheumatoid Arthritis in a United States Claims Database Initiating Abatacept and Other Biologic Disease-Modifying Antirheumatic Drugs: Analyses Using International Classification of Diseases Codes and a Published Claims Algorithm

9:00AM-11:00AM: Abstract Number: 577

Use of Subcutaneous MTX Does Not Prolong the Use of Traditional DMARD in Multi-DMARD Regimens and Has Insignificant Differences in Liver Enzymes Abnormalities When Compared with Oral MTX in Patients with Rheumatoid Arthritis: A Veteran Affairs Administrative Database Study

9:00AM-11:00AM: Abstract Number: 564

Value of Antinuclear Antibodies As a Predictor of Therapeutic Efficacy of Biologics in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 603

Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].